SOTAC — Sotac Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- IN₹1.89bn
- IN₹1.90bn
- IN₹579.83m
- 47
- 14
- 79
- 42
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
Standards: | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 286 | 488 | 732 | 580 |
Cost of Revenue | ||||
Gross Profit | 71.8 | 94.5 | 172 | 179 |
Selling / General / Administrative Expenses | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 281 | 500 | 681 | 514 |
Operating Profit | 4.62 | -11.4 | 50.1 | 65.8 |
Gain / Loss on Sale of Assets | ||||
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | 3.57 | -20.6 | 46.9 | 59.6 |
Provision for Income Taxes | ||||
Net Income After Taxes | 0.875 | -23.7 | 28.8 | 45 |
Net Income Before Extraordinary Items | ||||
Net Income | 0.875 | -23.7 | 28.8 | 45 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | 0.875 | -23.7 | 28.8 | 45 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | 0.052 | -2.14 | 3.62 | 5.58 |